NCT06769659招募中2 期
A Single-center, Double-blind, Placebo-controlled Crossover Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures
研究概览
简要总结
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
- •Subject is aged 16-75 years at the time of consent/assent
- •Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
- •Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
- •Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.
- •Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator
- •Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations
- •Subject has a body mass index (BMI) between 18 and 40 kg/m2 inclusive, at screening
- •Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug
- •Subject (and parent/caregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule
排除标准
- •Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.
- •Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)
- •Subject has a history of convulsive status epilepticus within the past year.
- •Subject has a history of surgical intervention for treatment of epilepsy
- •Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)
- •Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures
- •Female subject who is pregnant or lactating
- •Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study
- •Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results
- •Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:
- •Subject has active suicidal ideation prior to study entry as indicated by a positive response ("yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)
- •Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)
- •Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)
- •Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months
- •Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations
- •Subject is currently using prohibited medications or products
- •Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening
- •Subject (and parent/caregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits
- •Positive urine drug test for substance of abuse or illegal recreational substances at screening
研究组 & 干预措施
NPT 2042 80mg
Active Comparator
NPT 2042 80mg BID
干预措施: NPT 2042 (Drug)
NPT 2042 80mg
Active Comparator
NPT 2042 80mg BID
干预措施: Placebo (Other)
结局指标
主要结局
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures
时间窗: Up to 12 weeks
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.
次要结局
- Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures(Up to 12 weeks)
- The proportion of NPT 2042- vs. placebo-treated subjects meeting the study specific response criteria(Up to 12 weeks)
- The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)(Up to 12 weeks)
- The mean change from Baseline in the Digit Symbol Substitution Test(Up to 12 weeks)
- The mean change from Baseline in the Epworth Sleepiness Scale(Up to 12 weeks)
- Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure(Up to 12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)Perennial Allergic RhinitisNCT02709538Glenmark Specialty S.A.601
未知
3 期
Phase 3 study of GGS in patients with CSS/AGAChurg-Strauss Syndrome (CSS) / Allergic Granulomatous Angiitis (AGA)JPRN-jRCT2080220238TEIJIN PHARMA LIMITED21
已完成
2 期
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisUlcerative ColitisNCT04577794Galapagos NV31
已完成
2 期
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateRheumatoid ArthritisNCT04577781Galapagos NV28
已完成
2 期
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C SubjectsCirrhosis, LiverNCT00244751GlaxoSmithKline265